Cargando…
Therapeutic Drug Monitoring of Direct Oral Anticoagulants in Patients with Extremely Low and High Body Weight—Pilot Study
Phase III clinical trials for individual direct oral anticoagulants (DOACs) contained a limited representation of subjects with abnormal body weight, which were mostly limited to a BMI > 40 kg/m(2), or body weight > 120 kg for obese subjects, and <50 kg for underweight subjects. Although lo...
Autores principales: | Wołowiec, Łukasz, Kusiak, Mateusz, Budzyński, Jacek, Wołowiec, Anna, Jaśniak, Albert, Wiciński, Michał, Pedrycz-Wieczorska, Agnieszka, Rogowicz, Daniel, Grześk, Grzegorz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419712/ https://www.ncbi.nlm.nih.gov/pubmed/37568371 http://dx.doi.org/10.3390/jcm12154969 |
Ejemplares similares
-
Prognostic Value of Plasma Catestatin Concentration in Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up
por: Wołowiec, Łukasz, et al.
Publicado: (2023) -
MicroRNA and lncRNA as the Future of Pulmonary Arterial Hypertension Treatment
por: Wołowiec, Łukasz, et al.
Publicado: (2023) -
The Role of Selected Epigenetic Pathways in Cardiovascular Diseases as a Potential Therapeutic Target
por: Wołowiec, Anna, et al.
Publicado: (2023) -
The Clinical Significance of Drug–Food Interactions of Direct Oral Anticoagulants
por: Grześk, Grzegorz, et al.
Publicado: (2021) -
The Interactions of Nintedanib and Oral Anticoagulants—Molecular Mechanisms and Clinical Implications
por: Grześk, Grzegorz, et al.
Publicado: (2020)